Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury

Journal of Molecular and Cellular Cardiology

Volumn 64, Issue , 2013, Pages 11-19

  Oikawa, Masayoshi ^a,c   Wu, Meiping ^b   Lim, Soyeon ^a,e   Knight, Walter E ^a   Miller, Clint L ^a,f   Cai, Yujun ^a   Lu, Yan ^a   Blaxall, Burns C ^a,g   Takeishi, Yasuchika ^c   Abe, Jun ichi ^a   Yan, Chen ^a,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Yonsei University College of Medicine   (South Korea)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Cincinnati Childre's Hospital Medical Center   (United States)

Author keywords

Myocardial injury; Myocyte apoptosis; Myocyte contractility; PDE3A; Transgenic mice

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 3A1; HYDROGEN PEROXIDE; ICER PROTEIN; MILRINONE; PROTEIN BCL 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION SIZE; HEART INJURY; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REOXYGENATION; SIGNAL TRANSDUCTION; SURVIVAL; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

AAR; AREA AT RISK; B-CELL LYMPHOMA 2; BCL-2; BETA-ADRENERGIC RECEPTOR; CAMP-DEPENDENT PROTEIN KINASE TYPE A; CROSS-SECTIONAL AREA; CSA; EF; EJECTION FRACTION; GAPDH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEART WEIGHT; HW; I/R; ICER; INDUCIBLE CAMP EARLY REPRESSOR; ISCHEMIA/REPERFUSION; ISO; ISOPROTERENOL; LAD; LEFT ANTERIOR DESCENDING; LEFT VENTRICLE; LEFT VENTRICULAR DIASTOLIC DIAMETER; LEFT VENTRICULAR SYSTOLIC DIAMETER; LEFT VENTRICULAR SYSTOLIC PRESSURE; LUNG WEIGHT; LV; LV DP/DT MAX; LV DP/DT MIN; LVDD; LVDS; LVP; LW; MI; MIL; MILRINONE; MYOCARDIAL INFARCTION; MYOCARDIAL INJURY; MYOCYTE APOPTOSIS; MYOCYTE CONTRACTILITY; P-PLB; P-TNI; PDE3A; PDE3A1; PHOSPHODIESTERASE 3A1; PHOSPHOLAMBAN; PHOSPHORYLATED PHOSPHOLAMBAN; PHOSPHORYLATED TNI; PKA; PLB; ROL; ROLIPRAM; SARCOPLASMIC RETICULUM CALCIUM ATPASE TYPE 2; SERCA2; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE MEDIATED DUTP NICK END LABELING ASSAY; TG; THE MAXIMUM RATE OF LEFT VENTRICULAR PRESSURE DECREASE; THE MAXIMUM RATE OF LEFT VENTRICULAR PRESSURE RISE; TIBIA LENGTH; TL; TNC; TNI; TRANSGENIC MICE; TROPONIN C; TROPONIN I; TUNEL; WILD-TYPE MICE; WT; Β-AR;

ANIMALS; APOPTOSIS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEMODYNAMICS; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; ORGAN SPECIFICITY; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84883701893     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.08.003     Document Type: Article

References (55)

1. Movsesian M.A. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail Dec 2003, 9(6):475-480.
2. Xiang Y.K. Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circ Res Jul 8 2011, 109(2):231-244.
3. Wang X., Dhalla N.S. Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure. Mol Cell Biochem 2000, 214(1-2):131-155.
4. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 2003, 93(10):896-906.
5. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev Sep 2006, 58(3):488-520.
6. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology Nov 2010, 59(6):367-374.
7. DiBianco R. Clinical results with oral milrinone in heart failure. Eur Heart J Aug 1989, 10(Suppl. C):44-52.
8. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R.C., Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med Mar 16 1989, 320(11):677-683.
9. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325(21):1468-1475.
10. Nony P., Boissel J.P., Lievre M., Leizorovicz A., Haugh M.C., Fareh S., et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 1994, 46(3):191-196.
11. Sun B., Li H., Shakur Y., Hensley J., Hockman S., Kambayashi J., et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal Aug 2007, 19(8):1765-1771.
12. Beca S., Ahmad F., Shen W., Liu J., Makary S., Polidovitch N., et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res Jan 2013, 112(2):289-297.
13. Ding B., Abe J., Wei H., Huang Q., Walsh R.A., Molina C.A., et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation May 17 2005, 111(19):2469-2476.
14. Yan C., Ding B., Shishido T., Woo C.H., Itoh S., Jeon K.I., et al. Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res Mar 2 2007, 100(4):510-519.
15. Abi-Gerges A., Richter W., Lefebvre F., Mateo P., Varin A., Heymes C., et al. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res Oct 9 2009, 105(8):784-792.
16. Ma D., Fu L., Shen J., Zhou P., Gao Y., Xie R., et al. Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction. Eur J Pharmacol Jan 14 2009, 602(2-3):348-354.
17. Tomita H., Nazmy M., Kajimoto K., Yehia G., Molina C.A., Sadoshima J. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation. Circ Res 2003, 93(1):12-22.
18. Ding B., Abe J., Wei H., Xu H., Che W., Aizawa T., et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A Oct 11 2005, 102(41):14771-14776.
19. Itoh S., Ding B., Shishido T., Lerner-Marmarosh N., Wang N., Maekawa N., et al. Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation Apr 11 2006, 113(14):1787-1798.
20. Gulick J., Subramaniam A., Neumann J., Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991, 266(14):9180-9185.
21. Miller C.L., Oikawa M., Cai Y., Wojtovich A.P., Nagel D.J., Xu X., et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res Nov 6 2009, 105(10):956-964.
22. Das A., Xi L., Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem Apr 1 2005, 280(13):12944-12955.
23. Meacci E., Taira M., Moos M., Smith C.J., Movsesian M.A., Degerman E., et al. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci U S A May 1 1992, 89(9):3721-3725.
24. Smith C.J., Krall J., Manganiello V.C., Movsesian M.A. Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 1993, 190(2):516-521.
25. Itoh S., Ding B., Bains C.P., Wang N., Takeishi Y., Jalili T., et al. Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-{beta})-mediated cardiac troponin I phosphorylation. J Biol Chem Jun 24 2005, 280(25):24135-24142.
26. Maekawa N., Abe J., Shishido T., Itoh S., Ding B., Sharma V.K., et al. Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury. Circulation May 30 2006, 113(21):2516-2523.
27. Hua R., Adamczyk A., Robbins C., Ray G., Rose R.A. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium. PLoS One 2012, 7(10):e47652.
28. Tamargo J., Caballero R., Gomez R., Barana A., Amoros I., Delpon E. Investigational positive inotropic agents for acute heart failure. Cardiovasc Hematol Disord Drug Targets Sep 2009, 9(3):193-205.
29. Movsesian M., Stehlik J., Vandeput F., Bristow M.R. Phosphodiesterase inhibition in heart failure. Heart Fail Rev Dec 2009, 14(4):255-263.
30. Bristow M.R. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail Jun 2000, 6(2 Suppl. 1):8-14.
31. Sabbah H.N. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev Apr 2004, 9(2):91-97.
32. Du X.J., Gao X.M., Kiriazis H., Moore X.L., Ming Z., Su Y., et al. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res Sep 1 2006, 71(4):735-743.
33. Patrizio M., Musumeci M., Stati T., Fasanaro P., Palazzesi S., Catalano L., et al. Propranolol causes a paradoxical enhancement of cardiomyocyte foetal gene response to hypertrophic stimuli. Br J Pharmacol Sep 2007, 152(2):216-222.
34. Movsesian M.A., Alharethi R. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin Investig Drugs 2002, 11(11):1529-1536.
35. Khoo M.S., Li J., Singh M.V., Yang Y., Kannankeril P., Wu Y., et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation Sep 26 2006, 114(13):1352-1359.
36. Schrickel J.W., Lickfett L., Lewalter T., Tiemann K., Nickenig G., Baba H., et al. Cardiomyocyte-specific deletion of survivin causes global cardiac conduction defects. Basic Res Cardiol 2012, 107(6):299.
37. Trappe K., Thomas D., Bikou O., Kelemen K., Lugenbiel P., Voss F., et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J Jan 2013, 34(2):147-157.
38. Sanada S., Kitakaze M., Papst P.J., Asanuma H., Node K., Takashima S., et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation Aug 7 2001, 104(6):705-710.
39. Tosaka S., Makita T., Tosaka R., Maekawa T., Cho S., Hara T., et al. Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth 2007, 21(2):176-180.
40. Sandhu R., Thomas U., Diaz R.J., Wilson G.J. Effect of ischemic preconditioning of the myocardium on cAMP. Circ Res Jan 1996, 78(1):137-147.
41. Lochner A., Genade S., Tromp E., Opie L., Moolman J., Thomas S., et al. Role of cyclic nucleotide phosphodiesterases in ischemic preconditioning. Mol Cell Biochem Sep 1998, 186(1-2):169-175.
42. Saltman A.E., Gaudette G.R., Levitsky S., Krukenkamp I.B. Amrinone preconditioning in the isolated perfused rabbit heart. Ann Thorac Surg Aug 2000, 70(2):609-613.
43. Nomura Y., Horimoto H., Mieno S., Nakahara K., Okawa H., Yoshida M., et al. Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Mol Cell Biochem Jun 2003, 248(1-2):179-184.
44. Kwak H.J., Park K.M., Choi H.E., Park H.Y. Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells: role of PKC and COX-2. Free Radic Res Aug 2009, 43(8):744-752.
45. Andreadou I., Iliodromitis E.K., Farmakis D., Kremastinos D.T. To prevent, protect and save the ischemic heart: antioxidants revisited. Expert Opin Ther Targets Aug 2009, 13(8):945-956.
46. Liu S., Li Y., Kim S., Fu Q., Parikh D., Sridhar B., et al. Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts. Proc Natl Acad Sci U S A Apr 24 2012, 109(17):6578-6583.
47. Vila Petroff M.G., Egan J.M., Wang X., Sollott S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89(5):445-452.
48. Treiman M., Elvekjaer M., Engstrom T., Jensen J.S. Glucagon-like peptide 1-a cardiologic dimension. Trends Cardiovasc Med Jan 2010, 20(1):8-12.
49. Ravassa S., Zudaire A., Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res May 1 2012, 94(2):316-323.
50. Cohen M.V., Downey J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol May 2008, 103(3):203-215.
51. McIntosh V.J., Lasley R.D. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?. J Cardiovasc Pharmacol Ther Mar 2012, 17(1):21-33.
52. Okumura S., Takagi G., Kawabe J., Yang G., Lee M.C., Hong C., et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A 2003, 100(17):9986-9990.
53. Okumura S., Vatner D.E., Kurotani R., Bai Y., Gao S., Yuan Z., et al. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation Oct 16 2007, 116(16):1776-1783.
54. Takahashi T., Tang T., Lai N.C., Roth D.M., Rebolledo B., Saito M., et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation Aug 1 2006, 114(5):388-396.
55. Tang T., Gao M.H., Lai N.C., Firth A.L., Takahashi T., Guo T., et al. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation Jan 1 2008, 117(1):61-69.